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Available online 10 May 2016Hemophilia A is anX-linked recessive disorder causedby factor VIII deﬁciency,which is an important factor in the
coagulation system.Here,we describe a 1-year-old boywith hemophilia AwhodevelopedWest syndrome (WS).
Recombinant factor VIII was administered during adrenocorticotropic hormone (ACTH) therapy to prevent intra-
cranial hemorrhage. Infusion of factor VIII at ﬁxed intervals is useful for the safe administration of ACTH therapy
for patients with WS with severe hemophilia A. A coagulation screening test should be performed before ACTH
therapy.






West syndrome (WS) is themost common early-onset epileptic en-
cephalopathy and is characterized by infantile spasms, hypsarrhythmia
on electroencephalography (EEG), and developmental arrest or regres-
sion [1]. The etiology of WS is heterogeneous, including infections,
perinatal events, and congenital genetic disorders [2]. Although adreno-
corticotropic hormone (ACTH) is probably the most effective treatment
for WS, serious adverse effects can occur [3].
Hemophilia is a group of coagulation disorders that result from
blood coagulation factor deﬁciency. Hemophilia A is the most
common type of hemophilia and is an X-linked recessive disorder in-
duced by factor VIII deﬁciency, but reports of WS with hemophilia A
are rare [4]. Here, we describe a case ofWSwith severe hemophilia A.
2. Case report
The patient was a 1-year-old boy who was the second child of
healthy unrelated parents. His uncle on his mother's side suffered
from severe hemophilia A and received factor VIII infusions at ﬁxed
intervals. The patient was born by uncomplicated, normal vaginal
delivery at full term with a birth weight of 2405 g. At ages 4 and
7 months, he achieved head control and rollover, respectively. Al-
though social smile appeared at 4 months, it vanished at 6 months.fuUniversity Graduate School of
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7 months. From 6 months, he had recurrent episodes of seizure
with sudden ﬂexions of the upper and lower limbs 3–4 times a
week. He was referred to our hospital at age 1 year with a chief com-
plaint of daily seizures that occurred in clusters from 11 months.
Physical and neurological examinations were normal with no dys-
morphic features. Hemoglobin was 8.8 g/L, red blood cell (RBC)
count was 426 × 10/L, and coagulation studies revealed normal pro-
thrombin time (PT) and prolonged activated partial thromboplastin
time (aPTT) of 67.3 s (reference range: 25.0–43.0). Coagulation fac-
tor assay revealed severe factor VIII deﬁciency (b1 IU/mL). He was
diagnosed with severe hemophilia A. Interictal EEG showed very
high-amplitude slow waves mixed with spikes, suggesting
hypsarrhythmia. Brain magnetic resonance imaging (MRI) and com-
puted tomography (CT) results were normal. Based on
neuropsychomotor delay, EEG ﬁndings of hypsarrhythmia, and
spasms, which occurred in clusters, a diagnosis of WS was formed.
Vitamin B6 was administered as the ﬁrst treatment for WS but
was not effective. Although he received oral valproic acid and
zonisamide, spasms did not disappear. Finally, synthetic ACTH
(0.0125 mg/kg/day) was administered intramuscularly daily
for 2 weeks. Before ACTH therapy, factor VIII infusion test was
performed to determine the dosage of the coagulation factor.
Factor VIII levels were routinely measured, and an infusion of
factor VIII was performed at ﬁxed intervals to keep the trough
level N2 IU/dL to prevent lethal hemorrhage. Inhibitor levels were
also checked. While receiving ACTH, the previous medications of an-
tiepileptic drugs were continued. Adrenocorticotropic hormone
therapy achieved cessation of spasms after 7 days. Although brain
CT showed cerebellar atrophy, intracranial hemorrhage was not
observed.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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This patient had WS with severe hemophilia A. Adrenocorticotropic
hormone therapywas effective, and infusion of factor VIII at ﬁxed inter-
vals was useful for safe administration of ACTH therapy.
Our patient hadWSwith severe hemophilia A. The etiology of WS is
heterogeneous, including genetic and acquired causes such as hypoxic–
ischemic encephalopathy, tuberous sclerosis complex, chromosomal
disorders, cerebral malformations, infections, metabolic disorders, in-
tracranial hemorrhage (ICH), and stroke [2]. There are few reports of pa-
tients with hemophilia with nonsyndromic epilepsy. Only one case of
hemophilia A complicated with WS was reported [4]. The patient
showed no ICH by CT and MRI scans similar to our case.
Intracranial hemorrhage is a signiﬁcant complication for children
with hemophilia and occurs in approximately 5%of all untreated and se-
vere cases [5]. Neonatal ICH can be a presenting feature of severe cases
in about 3–4% [6]. Single remote symptomatic seizures often occur in
perinatal and childhood ICH, and 13%of childrenwith perinatal or child-
hood ICH developed epilepsy by 2 years of age [7]. Coagulopathy
accounts for 15% of the etiologies of ICH. Although Ganesan and
Kirkham suspected that a small ICH not detected by intracranial images
might trigger seizures in a patient with hemophilia A complicated with
WS [4], the underlying etiology of our case is unknown.
Adrenocorticotropic hormone therapy is a widely used and effective
treatment forWS. Signiﬁcant side effects of ACTH therapy include infec-
tion, hypertension, and cerebral atrophy with subsequent subdural he-
matoma [8]. Subdural hematoma results from tearing of the bridging
veins due to acute cerebral atrophy. Cerebral atrophy was observed in
all Japanese patients who were treated with ACTH, varying from mini-
mal tomassive [9]. Although it is generally accepted that the adverse ef-
fects of ACTH are dose-dependent, subdural hematomamay occur even
during administration of low-dose ACTH therapy [8]. Close monitoring
of adverse effects, especially subdural hematoma, is necessary. There-
fore, prophylactic infusions of factor VIII were performed every other
day to prevent subdural hematoma and other bleeding episodes. Our
patient completed ACTH treatment without severe adverse effects.
Then, infusionwith the coagulation factor at ﬁxed intervalsmight be re-
quired for the safe administration of ACTH therapy for patients withWS
with coagulopathy.
The diagnosis of hemophilia in our case was based on the existence
of family history. The reliability of clinical history might be low, and
family history might not be helpful for patients with inheritedcoagulopathy resulting from spontaneous mutation or the variable ex-
pression of a coagulopathy [10]. Indeed, marked bruising and hemato-
ma at the intramuscular injection site of ACTH may lead to the
diagnosis of hemophilia A without family history [4]. Some children
with bleeding disorders may be identiﬁed ﬁrst during preoperative co-
agulation testing. Thus, coagulation screening prior to ACTH therapy
should be routinely performed to prevent potentially fatal bleeding.
In conclusion, we report that an infusion of factor VIII at ﬁxed inter-
vals should be used for the safe administration of ACTH therapy for pa-
tients with WS with severe hemophilia A. Because the identiﬁcation of
pediatric patients at risk of hemorrhage before ACTH therapy might re-
sult in a change in management of treatment, coagulation screening
tests should be performed prior to ACTH therapy.
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